સન ફાર્મા ઍડવાન્સ્ડ રિસર્ચ કંપની શેર કિંમત

Pharmaceuticals company Sun Pharma Advanced Research Company announced Q4FY26 & FY26 results Consolidated Financial Highlights Revenue from Operations: For Q4FY26, consolidated revenue from operations stood at Rs 1,85,322 lakh, reflecting a significant growth of 6,715.81% compared to Rs 2,719 lakh in Q4FY25. It also grew substantially on a QoQ basis from Rs 845 lakh in Q3FY26. Total Income: The total income for Q4FY26 was Rs 1,85,502 lakh, up from Rs 2,719 lakh in Q4FY25 and Rs 845 lakh in Q3FY26. Annual Revenue: For the full year FY26, consolidated revenue reached Rs 1,87,917 lakh, a 2,518.32% increase over Rs 7,177 lakh in FY25. Net Profit: The Group recorded a net profit of Rs 1,76,134 lakh in Q4FY26, compared to a net loss of Rs 5,977 lakh in Q4FY25 and a net loss of Rs 8,042 lakh in Q3FY26. Annual Net Profit: For the full year FY26, the Group reported a net profit of Rs 1,55,320 lakh, as against a net loss of Rs 34,251 lakh in FY25. Total Comprehensive Income: For Q4FY26, it stood at a profit of Rs 1,76,269 lakh, compared to a loss of Rs 6,016 lakh in Q4FY25. For the full year FY26, total comprehensive profit was Rs 1,55,577 lakh compared to a loss of Rs 34,270 lakh in FY25. Standalone Financial Highlights Total Income: Standalone total income for Q4FY26 was Rs 1,85,502 lakh, compared to Rs 2,719 lakh in Q4FY25 and Rs 845 lakh in Q3FY26. Annual standalone total income for FY26 was Rs 1,89,000 lakh, up from Rs 7,356 lakh in FY25. Revenue from Operations: Standalone revenue for Q4FY26 stood at Rs 1,85,322 lakh, an increase from Rs 2,719 lakh in Q4FY25 and Rs 845 lakh in Q3FY26. Annual revenue for FY26 was Rs 1,87,917 lakh. Net Profit: The company reported a standalone net profit of Rs 1,76,070 lakh for Q4FY26, against a loss of Rs 6,098 lakh in Q4FY25 and a loss of Rs 8,057 lakh in Q3FY26. Annual Net Profit: Standalone net profit for FY26 reached Rs 1,55,213 lakh, compared to a loss of Rs 34,522 lakh in FY25. Business Highlights Segment Performance: The company operates in a single reportable business segment, namely 'Pharmaceutical Research and Development'. Priority Review Voucher (PRV) Income: A major highlight for the quarter was the recognition of Rs 1,84,002 lakh in income under 'Other operating revenue'. This income pertains to a Priority Review Voucher (PRV) granted by the United States Food and Drug Administration (USFDA) on February 03, 2026, for Sezaby. The PRV was subsequently sold by the company on April 30, 2026, for USD 195 million. Labour Code Exceptional Item: The company assessed the implications of the New Labour Codes (Code on Wages, 2019, etc.) and recognised an incremental cost of Rs 1,236 lakh during the quarter ended December 31, 2025, which has been disclosed as an exceptional item in the annual results. Auditor Opinion: The statutory auditors, S R B C & CO LLP, have expressed an unmodified opinion on the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Result PDF

• ટ્રેન્ડલાઇન
• 2 અઠવાડિયા 2 દિવસ પહેલાં

ફાર્માસ્યુટિકલ્સ કંપની સન ફાર્મા એડવાન્સ્ડ રિસર્ચ કંપનીએ જાહેરાત કરી છે કે Q3FY26 પરિણામો એકીકૃત આવક ₹ 845 લાખ (ઓછી 43% વર્ષ) છે. એકીકૃત ખર્ચ 19% YoY થી ₹7,644 લાખ સુધી ઘટી ગયા છે; પેટાકંપનીઓને કારણે કર્મચારી ખર્ચ ₹3,118 લાખ પર સ્ટેન્ડ-અલોન સ્તર કરતાં વધુ હતો. અસાધારણ વસ્તુઓ અને ટૅક્સ પહેલાં એકીકૃત નુકસાન ₹ 6,799 લાખ હતું (Q3FY25: નુકસાન ₹ 7,944 લાખ). ટૅક્સ પછી એકીકૃત નુકસાન ₹ 8,042 લાખ (Q3FY25 નુકસાન ₹ 7,951 લાખ) સુધી પહોંચી ગયું છે. કન્સોલિડેટેડ બેસિક અને ડાઇલ્યુટેડ ઇપીએસ - ₹ 2.48 (Q3FY25 -₹ 2.45). પરિણામની PDF

• ટ્રેન્ડલાઇન
• 3 મહિના 3 અઠવાડિયા પહેલાં

બુધવારે સાંજે 12.26 વાગ્યે, સ્પાર્કના શેર 159.90 પર -18.25 ટકા ઘટીને હતા

• બિઝનેસ લાઇન
• 1 વર્ષ પહેલાં